We are developing fundamental drug discovery technologies for small molecules and macromolecules, which are the main class of commercial drugs, and for “undruggable” biomacromolecules, which cannot be targeted by polymers, to develop therapeutic drugs.

In the drug discovery platform technology business, we are developing new types of functional molecules that have not been reported anywhere in the world through precise molecular design and the world's most advanced computational chemistry. In the cross-linked peptide patent, we are developing large-scale screening methods using artificial amino acids and cross-linked peptides as inventions.

In the drug discovery business, we are mainly engaged in the development of therapeutics for “undruggable” biomacromolecules.